Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
Basel, 22 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA study evaluating investigational giredestrant in combination with everolimus in
3 Potential Biotech Acquisition Targets
12:53pm, Friday, 19'th Sep 2025
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 8
Basel, 19 September - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a su
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
12:41pm, Thursday, 18'th Sep 2025
Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline.
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push
12:34pm, Thursday, 18'th Sep 2025
On Thursday, Roche Holdings AG RHHBY agreed to acquire 89bio, Inc. ETNB for $2.4 billion. 89Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therap
Roche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total test
10:00am, Thursday, 18'th Sep 2025
First mass spectrometry-based test system for total 25-Hydroxyvitamin D to receive CLIA 'Moderate Complexity' designation in the U.S. Expands access to advanced testing with a fully automated, standar
Roche to buy US biotech 89bio in $3.5bn deal
03:07am, Thursday, 18'th Sep 2025
Roche has agreed to acquire American biotech 89bio in a transaction worth up to $3.5 billion, as it looks to expand its pipeline of treatments for liver and cardiometabolic diseases. The Swiss pharmac
Roche to Buy 89bio for Up to $3.5 Billion
01:29am, Thursday, 18'th Sep 2025
The deal seeks to strengthen the drugmaker's pipeline by adding an experimental drug for an obesity comorbidity.
Roche to acquire liver drug developer 89bio for up to $3.5 billion
01:18am, Thursday, 18'th Sep 2025
Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio ETNB.O for up to $3.5 billion to strengthen its development pipeline on liver and cardiometabolic disease treatments.
89bio, Inc. Announces Agreement to be Acquired by Roche
01:02am, Thursday, 18'th Sep 2025
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.
Basel, 18 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a publicly listed clinical-s
The integration of Accu-Chek SmartGuide's AI-enabled predictive CGM with the popular mySugr app delivers a simple, intuitive solution for people to manage their diabetes with greater ease. Accu-Chek S
RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress
11:16am, Friday, 05'th Sep 2025
Roche posts strong new data for Vabysmo in eye disease, with extended dosing and vision gains driving growth.
New Data for Genentech's Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
01:00am, Friday, 05'th Sep 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (farici
